Skip to main content
Erschienen in: Tumor Biology 9/2015

01.09.2015 | Research Article

MicroRNA signatures in total peripheral blood of gallbladder cancer patients

verfasst von: Gangqiang Li, Yabin Pu

Erschienen in: Tumor Biology | Ausgabe 9/2015

Einloggen, um Zugang zu erhalten

Abstract

MicroRNAs (miRNAs) are small non-coding RNA molecules that function as negative regulators of gene expression. Expression analysis of miRNAs can reflect the developmental lineage and differentiation state of the tumor. Thus, the miRNA profiles could play essential roles in gallbladder cancer (GBC). However, their role as novel biomarkers for the diagnosis of GBC is unclear yet. We assessed here for the first time whole-genome miRNA expression in peripheral blood samples of 40 GBC patients using microRNA microarray. We identified 11 miRNAs, which are significantly dysregulated in GBC patients in comparison to 40 healthy controls. Among these, the expression of let-7a, miR-21, miR-187, miR-143, miR-202, and miR-335 are in agreement with those measured by real-time PCR (p < 0.05). Furthermore, dysregulated miR-187, miR-143, and miR-202 demonstrate a significant correlation with clinicopathologic features (p < 0.05). Our results suggest a possible pathological relationship between the differential expression of miRNA in peripheral blood and GBC, and these dysregulated miRNAs could be novel tumor biomarkers for early detection of GBC.
Literatur
1.
Zurück zum Zitat Dutta U. Gallbladder cancer: can newer insights improve the outcome? J Gastroenterol Hepatol. 2012;27(4):642–53.CrossRefPubMed Dutta U. Gallbladder cancer: can newer insights improve the outcome? J Gastroenterol Hepatol. 2012;27(4):642–53.CrossRefPubMed
2.
Zurück zum Zitat Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49.CrossRefPubMed Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49.CrossRefPubMed
3.
Zurück zum Zitat Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–66.CrossRefPubMed Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–66.CrossRefPubMed
4.
Zurück zum Zitat Su M, Zhao X. Dignostic value of detection of CA19-9,CEA,AFP and CA125in gallbladder carcinoma patients. Med J PAPF. 2008;9(10):906–8. Su M, Zhao X. Dignostic value of detection of CA19-9,CEA,AFP and CA125in gallbladder carcinoma patients. Med J PAPF. 2008;9(10):906–8.
5.
Zurück zum Zitat Wang F, Zheng Z, Guo J, et al. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol. 2010;119(3):586–93.CrossRefPubMed Wang F, Zheng Z, Guo J, et al. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol. 2010;119(3):586–93.CrossRefPubMed
6.
Zurück zum Zitat Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. Plos One. 2008;3(9):3138–45.CrossRef Gilad S, Meiri E, Yogev Y, et al. Serum microRNAs are promising novel biomarkers. Plos One. 2008;3(9):3138–45.CrossRef
7.
Zurück zum Zitat Huang Y, Shen XJ, Zou Q, et al. Biological functions of microRNAs: a review. J Physiol Biochem. 2011;67(1):129–39.CrossRefPubMed Huang Y, Shen XJ, Zou Q, et al. Biological functions of microRNAs: a review. J Physiol Biochem. 2011;67(1):129–39.CrossRefPubMed
8.
Zurück zum Zitat Chan SH, Wu CW, Li AF, et al. mir-21 microRNA expression in human gastric carcinomas and its clinical association. Anticancer Res. 2008;28(2):907–11.PubMed Chan SH, Wu CW, Li AF, et al. mir-21 microRNA expression in human gastric carcinomas and its clinical association. Anticancer Res. 2008;28(2):907–11.PubMed
9.
Zurück zum Zitat Michael MZ, O’Connor SM, Van Holst Pellekaan NG, et al. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res. 2003;1(12):882–91.PubMed Michael MZ, O’Connor SM, Van Holst Pellekaan NG, et al. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res. 2003;1(12):882–91.PubMed
10.
Zurück zum Zitat Shell R, Park SM, Radjabi AR, et al. Let-7 expression defines two differentiation stages of cancers. Proc Natl Acad Sci U S A. 2007;104(27):11400–5.CrossRefPubMedPubMedCentral Shell R, Park SM, Radjabi AR, et al. Let-7 expression defines two differentiation stages of cancers. Proc Natl Acad Sci U S A. 2007;104(27):11400–5.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Yu F, Yao H, Zhu P, et al. Let-6 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007;131(6):1109–23.CrossRefPubMed Yu F, Yao H, Zhu P, et al. Let-6 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007;131(6):1109–23.CrossRefPubMed
12.
Zurück zum Zitat Szafranska AE, Davision TS, John J, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 2007;28(26):4442–52.CrossRef Szafranska AE, Davision TS, John J, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 2007;28(26):4442–52.CrossRef
13.
Zurück zum Zitat Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular cancinoma. J Clin Oncol. 2011;29(36):4781–8.CrossRefPubMed Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular cancinoma. J Clin Oncol. 2011;29(36):4781–8.CrossRefPubMed
14.
Zurück zum Zitat Chao A, Lin CY, Lee YS, et al. Regulation of ovarian cancer progression by microRNa-187 through targeting disabled homolog-2. Oncogene. 2011;10(7):269–73. Chao A, Lin CY, Lee YS, et al. Regulation of ovarian cancer progression by microRNa-187 through targeting disabled homolog-2. Oncogene. 2011;10(7):269–73.
15.
Zurück zum Zitat Song T, Zhang X, Wang C, et al. Expression of miR-143 reduces growth and migration of human bladder carcinoma cells by targeting cyclooxygenase-2. Asian Pac J Cancer Prev. 2011;12(4):929–33.PubMed Song T, Zhang X, Wang C, et al. Expression of miR-143 reduces growth and migration of human bladder carcinoma cells by targeting cyclooxygenase-2. Asian Pac J Cancer Prev. 2011;12(4):929–33.PubMed
16.
Zurück zum Zitat Huang HY, Cheng YY, Liao WC, et al. SoX4 transcriptionally regulates multipleSEMA3/plexin family members and promotes tumor growth in pancreatic cancer. Plos One. 2012;7(12):48637–742.CrossRef Huang HY, Cheng YY, Liao WC, et al. SoX4 transcriptionally regulates multipleSEMA3/plexin family members and promotes tumor growth in pancreatic cancer. Plos One. 2012;7(12):48637–742.CrossRef
17.
Zurück zum Zitat Zu Y, Ban J, Xia Z, et al. Genetic variation in a miR-335 binding site in BIRC5 alters susceptibility to lung cancer in Chinese Han population. Biochem Biophys Res Commun. 2013;430(2):529–34.CrossRefPubMed Zu Y, Ban J, Xia Z, et al. Genetic variation in a miR-335 binding site in BIRC5 alters susceptibility to lung cancer in Chinese Han population. Biochem Biophys Res Commun. 2013;430(2):529–34.CrossRefPubMed
18.
Zurück zum Zitat Hu Y, Ou Y, Wu K, et al. miR-143 inhibits the metastasis of pancreatic cancer and an associated signaling pathway. Tumor Biol. 2012;33(6):1863–70.CrossRef Hu Y, Ou Y, Wu K, et al. miR-143 inhibits the metastasis of pancreatic cancer and an associated signaling pathway. Tumor Biol. 2012;33(6):1863–70.CrossRef
19.
Zurück zum Zitat Koberle V, Kronenberger B, Pleli T, et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer. 2013;49(16):3442–9.CrossRefPubMed Koberle V, Kronenberger B, Pleli T, et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer. 2013;49(16):3442–9.CrossRefPubMed
20.
Zurück zum Zitat Ma Y, Zhang P, Wang F, et al. Mir-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut. 2012;61(10):1447–53.CrossRefPubMed Ma Y, Zhang P, Wang F, et al. Mir-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut. 2012;61(10):1447–53.CrossRefPubMed
Metadaten
Titel
MicroRNA signatures in total peripheral blood of gallbladder cancer patients
verfasst von
Gangqiang Li
Yabin Pu
Publikationsdatum
01.09.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 9/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3412-4

Weitere Artikel der Ausgabe 9/2015

Tumor Biology 9/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.